Treatment Sequencing and Line of Therapy for Biologics and <scp>JAK</scp> inhibitors in Rheumatoid Arthritis Patients: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics
These findings highlight the size and characteristics of the eligible RA population in the U.S. initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker-based diagnostic tests to predict future treatment response.
Authors
- E. Blair Holladay
- J. Randall Curtis (ORCID: https://orcid.org/0000-0001-9529-845X)
- Amy S. Mudano
- Shanette Daigle
- Yujie Su
- Priya Reddy
- Gordon Lam
- Michael George
- Robert Levin
- Fenglong Xie
Institutions
- Atrium Health Wake Forest Baptist (US)
- Foundation for Advancement of International Medical Education and Research (US)
- University of South Florida (US)
- Riverview Hospital (CA)
- University of Alabama at Birmingham (US)
- Clinical Research of West Florida (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1002/acr.80025
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health